AstraZeneca Pharma India Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from AstraZeneca Pharma India Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in India.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹17Over the last 3 years, every ₹100 of reported profit came with ₹17 of operating cash.
Lower than 88% of Healthcare companies in India.
Self-Funding Ratio
4.8×Over the last 3 years its own operating cash covered its investment spending (capex) 4.8 times.
Higher than 91% of Healthcare companies in India.
Cash Locked Ratio
₹19For every ₹100 of sales, ₹19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹4 tied up three years earlier.
Less money tied up than 62% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹7Sales grew 127% in 3 years; of every extra ₹100 of sales, ₹7 became extra profit.
Lower than 75% of Healthcare companies in India.
Asset Productivity Ratio
+127% / +102%In 3 years sales changed by +127% while total assets changed by +102%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-1.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 70% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
AstraZeneca Pharma India Limited owes ₹0.56 for every ₹1 it owns. Net profit rose 62% in the year to Mar 2026, and grew 24% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
88.3Investors pay ₹88.3 for every ₹1 of AstraZeneca Pharma India Limited's yearly profit, higher than 89% of Healthcare companies in India.
P/B ratio
17.15The share price is 17.15 times AstraZeneca Pharma India Limited's book value per share, higher than 96% of Healthcare companies in India.
Market cap
₹14,971 CrThe total market value of all of AstraZeneca Pharma India Limited's shares at today's price (share price × number of shares), larger than 72% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹873 CrWhat AstraZeneca Pharma India Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹349.12Net worth divided by the number of shares. The share price of ₹5,988 is 17.2 times this, which is the P/B above.
Return on equity (ROE)
19.4%AstraZeneca Pharma India Limited earned 19.4% on its shareholders' money over the last year, higher than 78% of Healthcare companies in India.
Owes vs Owns
0.56×AstraZeneca Pharma India Limited owes ₹0.56 for every ₹1 it owns (moderate), higher than 90% of Healthcare companies in India.
Dividend yield
0.62%AstraZeneca Pharma India Limited pays 0.62% of its share price as dividends a year, higher than 69% of dividend-paying Healthcare companies in India.
Revenue growth
+33%Revenue rose 33% in the year to Mar 2026, and grew 31% a year on average over 3 years.
Profit growth
+62%Net profit rose 62% in the year to Mar 2026, and grew 24% a year on average over 3 years.
Profit margin
8.3%AstraZeneca Pharma India Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
-0.1×Cash from AstraZeneca Pharma India Limited's business was -0.1× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
52.3×AstraZeneca Pharma India Limited's operating profit covered its interest costs 52.3 times in the year to Mar 2026.
Cash vs debt
Net cashAstraZeneca Pharma India Limited held ₹337 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is AstraZeneca Pharma India Limited's P/E ratio?
Investors pay ₹88.3 for every ₹1 of AstraZeneca Pharma India Limited's yearly profit, higher than 89% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For AstraZeneca Pharma India Limited: ₹14,971 Cr ÷ ₹873 Cr (31 Mar 2026) = 17.2.
What is AstraZeneca Pharma India Limited's return on equity?
AstraZeneca Pharma India Limited earned 19.4% on its shareholders' money over the last year, higher than 78% of Healthcare companies in India.
How much does AstraZeneca Pharma India Limited owe compared with what it owns?
AstraZeneca Pharma India Limited owes ₹0.56 for every ₹1 it owns (moderate), higher than 90% of Healthcare companies in India.
Does AstraZeneca Pharma India Limited pay a dividend?
Yes. AstraZeneca Pharma India Limited pays 0.62% of its share price as dividends a year, higher than 69% of dividend-paying Healthcare companies in India.
Is AstraZeneca Pharma India Limited's revenue growing?
Revenue rose 33% in the year to Mar 2026, and grew 31% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.